Clinical trials: Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Adult Solid Tumor, Protocol Specific
Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment
RATIONALE: Questionnaires that measure how well older patients think, learn, remember, and make judgments and carry out daily activities may improve the ability to plan treatment for patients with cancer.
- Trial name
- NCT01005693
- Testing
- questionnaire administration, cognitive assessment, examination
- Where
- 4 sites in Belgium
- Volunteers
- 300 people
- Sponsor
- Ziekenhuis Netwerk Antwerpen (ZNA)
Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers
The rationale for conducting this study lies in the premise that if indeed the reason for a limited response of Kaposi's sarcoma lesions and other advanced malignancies to chemotherapy is attributable to a high expression of…
- Trial name
- NCT00003207
- Testing
- pegylated liposomal doxorubicin hydrochloride, PSC 833
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Washington University School of Medicine
Unspecified Adult Solid Tumor, Protocol Specific
Health Education in Improving the Understanding of Medical Information
RATIONALE: Understanding the risk of disease and prevention and screening activities to lower disease risk may help individuals make informed medical decisions.
- Trial name
- NCT00387998
- Testing
- AHRQ staying healthy booklet, Risk primer
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab in Treating Patients With Advanced Solid Tumors
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00416637
- Testing
- Bevacizumab (Avastin)
- Volunteers
- 27 people
- Sponsor
- Herbert Hurwitz, MD
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Valdecoxib in Treating Chronic Pain in Cancer Patients
RATIONALE: Valdecoxib may be effective in relieving chronic pain in cancer patients. It is not yet known if valdecoxib is effective in treating chronic pain.
- Trial name
- NCT00021996
- Testing
- valdecoxib
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Chemotherapeutic Agent Toxicity, Neurotoxicity
Acute Pain Caused by Paclitaxel in Patients With Cancer
RATIONALE: Gathering information over time from patients receiving paclitaxel for cancer may help doctors learn more about pain caused by paclitaxel and plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00860041
- Testing
- pain questionnaires
- Where
- 279 sites in United States
- Volunteers
- 306 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving…
- Trial name
- NCT00553059
- Testing
- dexamethasone, dronabinol, palonosetron hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
SU5416 in Treating Patients With Advanced Solid Tumors
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have advanced solid tumors.
- Trial name
- NCT00005642
- Testing
- semaxanib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Assessing Older Patients With Cancer
RATIONALE: Questionnaires that measure the ability of older patients to think, learn, remember, and make judgments and carry out daily activities may improve the ability to plan treatment for patients with cancer.
- Trial name
- NCT00416481
- Testing
- quality of life questionnaires
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Unspecified Adult Solid Tumor, Protocol Specific, Vascular Access Device Complications
Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy
RATIONALE: Giving chemotherapy drugs through an implanted port reduces the need for multiple needle sticks. It is not yet known whether one type of port is more effective than another in reducing infections and other side effects…
- Trial name
- NCT00607880
- Testing
- vascular access device placement
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Lymphoma, Small Intestine Cancer
ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00016172
- Testing
- pegylated liposomal doxorubicin hydrochloride, picoplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure. PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan…
- Trial name
- NCT01234922
- Testing
- lisinopril, losartan potassium, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Unspecified Adult Solid Tumor, Protocol Specific
Dietary Soy Isoflavones for the Prevention of Cancer
RATIONALE: Eating a diet rich in soy foods appears to reduce the risk of some types of cancer. Isoflavones are compounds found in soy food that may prevent the development of cancer.
- Trial name
- NCT00003100
- Testing
- soy isoflavones
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain
RATIONALE: Naloxone may be effective in treating constipation that may be caused by opioid pain medications such as morphine. PURPOSE: Phase III trial to determine the effectiveness of naloxone in relieving constiption in…
- Trial name
- NCT00020605
- Testing
- naloxone hydrochloride
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.
- Trial name
- NCT01898130
- Testing
- bevacizumab, quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University